{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"nad-plus",
"title":"nad plus",
"kind":"standard",
"summary":"Evidence is being populated by Grok web",
"created":"2026-06-29T17:09:32.135Z",
"body": [
"## Overview\nEvidence is being populated by Grok web search."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T17:09:55.259Z",
"register":"standard",
"category":null
},
"sources": [
{
"id":"s1",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/37971292/",
"title":"Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review",
"quote":"This review includes 10 studies, with a total of 489 participants. ... NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.",
"summary":"2024 systematic review of RCTs on NAD+/NADH supplementation safety and efficacy across conditions like CFS, Parkinson's, Alzheimer's; concludes well-tolerated with some benefits in quality of life and parameters, low side effects.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:32.261Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"genesis",
"hash":"869513647d4f7588142f478728e329e0365fdb47c4097d349c753f32df3e7491",
"quote_sha256":"b907b031b16fd06640a4aa78adbe49517238015717ddbb3e91b91435ab9e708e"
},
{
"id":"s2",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/41655607/",
"title":"NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence",
"quote":"We identified 113 eligible studies: 33 human intervention studies (28 randomized; 5 nonrandomized) and 80 rodent studies. ... Overall, NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive.",
"summary":"2026 PRISMA systematic review of 113 studies (up to Oct 2025) on NAD+ precursors; strong preclinical effects, human trials show NAD boosting and tolerability but heterogeneous/inconclusive functional outcomes; calls for larger trials.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:32.261Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"869513647d4f7588142f478728e329e0365fdb47c4097d349c753f32df3e7491",
"hash":"822ba9e2aaf73280d08236720d9f832a0e3ee3a82123407d5eae116d49166b00",
"quote_sha256":"a2d6ee417b86672ea39623c7c08d250e81c5961d3b465fbfde1b21583ae302c6"
},
{
"id":"s3",
"type":"clinical_trial",
"url":"https://pubmed.ncbi.nlm.nih.gov/40479886/",
"title":"Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial",
"quote":"Preliminary results indicate a positive trend in peripheral endothelial function, significant improvements in cerebrovascular response in the left dorsolateral prefrontal cortex, and cognitive enhancement across multiple domains postsupplementation. ... These findings suggest that NR supplementation could ameliorate cognitive outcomes in older adults with PAD.",
"summary":"2025 pilot open-label trial (NCT06534944) of NR in 8 older PAD patients; showed trends/improvements in endothelial function, cerebrovascular responses, cognition, and in vitro endothelial benefits via reduced oxidative stress.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:32.261Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"822ba9e2aaf73280d08236720d9f832a0e3ee3a82123407d5eae116d49166b00",
"hash":"a7eac5f034f16239c03d81c53c53248fddebba7aae23d702345e12aa1a77e5c6",
"quote_sha256":"7452d8efce75f2d8f9453ecd08ad193cd66165772880fe9535c67310455fe839"
},
{
"id":"s4",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40954388/",
"title":"Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial",
"quote":"This study has confirmed that supplementation with NAD+ can enhance cardiac function in patients with from HF due to ICM, thereby affirming its beneficial impact on cardiac performance.",
"summary":"2026 RCT showing IV NAD+ improves LVEF and trends toward better outcomes in heart failure patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:54.587Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"a7eac5f034f16239c03d81c53c53248fddebba7aae23d702345e12aa1a77e5c6",
"hash":"157174255e4fcde7e87c20f630ec7e13746a109becc869b702de1747b9747c38",
"quote_sha256":"3acccd83f9584c2e182d282c0be06e66b2315f851f5f679ca91cbd282efc63e5"
},
{
"id":"s5",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41540253/",
"title":"The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans",
"quote":"Here we show in a randomized, open-label, placebo-controlled study in 65 healthy participants that 14 days of supplementation with NR and NMN, but not Nam, comparably increases circulatory NAD + concentrations in healthy adults.",
"summary":"2026 RCT comparing NR, NMN, and Nam effects on NAD levels and gut microbiota.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:54.587Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"157174255e4fcde7e87c20f630ec7e13746a109becc869b702de1747b9747c38",
"hash":"e8af32efc5694522778f2a43384a68b781f822f1bc3a5be7610b71d54d109208",
"quote_sha256":"692b9eccd6eaa57dfb82be59dc5920d61b8ef101d992718051edb728f69137df"
},
{
"id":"s6",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41083806/",
"title":"NAD+ precursor supplementation in human ageing: clinical evidence and challenges",
"quote":"In this Review, we evaluate the clinical evidence supporting the notion that NAD + levels decline with age, as well as the tissue-specific effects of NAD + precursor supplementation in humans.",
"summary":"Recent review on clinical evidence for NAD+ precursors in aging.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:54.587Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e8af32efc5694522778f2a43384a68b781f822f1bc3a5be7610b71d54d109208",
"hash":"f6121f80d6ef9da89b1e4addb8a62c6f7ca188c454f1859a2b94f091dfe460d2",
"quote_sha256":"fa7656d6b7595f2ce1398cf36f2de6bcf8553dbcc79f7a6edccfd456c9537906"
},
{
"id":"s7",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41704678/",
"title":"Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting",
"quote":"Supplementation with NAD + and its precursors is commonly used to prevent age-related disease and extend healthspan.",
"summary":"2026 pilot study comparing IV NAD+ and NR tolerability.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:09:54.587Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"f6121f80d6ef9da89b1e4addb8a62c6f7ca188c454f1859a2b94f091dfe460d2",
"hash":"649a99782648d1dcc12c936eb9ea8870f24ca71ef7598348b79d1ee248e49abf",
"quote_sha256":"0a8306a700dc02bbf03f6eac00be0e37176d95670d1918c84e46a92fd6aeec73"
}
],
"type":"article",
"updated":"2026-10-08T11:49:39.101Z",
"version":1,
"hash":"d6d358efb60aa16c55bb9d251d0d3fbb2caef317bbf6e463578d96c02a615061",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/nad-plus",
"json":"https://miscsubjects.com/a/nad-plus.json",
"markdown":"https://miscsubjects.com/a/nad-plus.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/nad-plus",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/nad-plus.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/nad-plus.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/nad-plus",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/nad-plus/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/nad-plus/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/nad-plus",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/nad-plus",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"nad-plus",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/nad-plus/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"nad-plus"
}
}
]
}